Tag: Medicare Part B reimbursement
Biosimilars are billed differently than generics under Medicare Part B. Each has its own HCPCS code and payment rate based on its ASP plus 6% of the reference product’s price. This system encourages biosimilar entry but doesn’t strongly incentivize switching. Learn how billing works and why adoption remains low in the U.S.
Categories
Archives
Recent-posts
Therapeutic Drug Monitoring for Generic NTIs: Protecting Patients on Antiretroviral Therapy
Feb, 26 2026

Medications